ASCO 2023 | TROPiCS-02: sacituzumab govitecan in HR+/HER2- breast cancer

Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of the rationale and trial design of the TROPiCS-02 trial (NCT03901339), which assessed sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate (ADC), in patients with pretreated HR+/HER2– metastatic breast cancer. Previous studies have shown that the ADC improved survival in patients and the current trial randomized patients to either receive sacituzumab govitecan or physician’s choice of chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.